Difference between revisions of "Team:AQA Unesp"

 
(329 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 +
{{AQA_Unesp_nav}}
 +
 
<html>
 
<html>
−
<head>
+
<body>
−
<link href="https://fonts.googleapis.com/css?family=Quicksand" rel="stylesheet">
+
 
 
<style>
 
<style>
  
 +
.foto-grande {
 +
background: url(https://static.igem.org/mediawiki/2017/6/68/Aqaunesp-main-header.png) no-repeat center center;
 +
width: 100%;
 +
height: 100vh;
 +
overflow:hidden;
 +
background-size: cover;
 +
padding: 5% 0;
 +
}
  
 +
@font-face {
 +
    font-family: caviardreams;
 +
    src: url('https://static.igem.org/mediawiki/2017/4/43/Aqaunesp-caviardreams.ttf');
 +
}
  
−
/***************************************************** DEFAULT WIKI SETTINGS  ****************************************************/
+
.insubiota-text {  font:12em caviardreams, sans-serif; text-align: center; color:white }
−
+
−
/* Clear the default wiki settings */
+
−
+
−
#home_logo, #sideMenu { display:none; }
+
−
#sideMenu, #top_title, .patrollink  {display:none;}
+
−
#content { width:100%; padding:0px; margin-top:-7px; margin-left:0px;}
+
−
body {background-color:white; }
+
−
#bodyContent h1, #bodyContent h2, #bodyContent h3, #bodyContent h4, #bodyContent h5 { margin-bottom: 0px; }
+
  
−
+
.insubiota-subtext {  font:2em caviardreams, sans-serif; text-align: center; color:white; }
−
+
  
−
/***************************************************** CONTENT OF THE PAGE ****************************************************/
+
#titleinsubiota {padding: 10% 0;}
  
−
html, body {
+
#abstract { font:5em caviardreams, sans-serif; text-align: center; color: white; font-weight:bold; padding-top: 2%}
−
height: 100%;
+
−
min-height: 100%;
+
−
margin: 0px;
+
−
background-color: #6c0d00;
+
−
}
+
−
+
−
.coming-soon {
+
−
height: 100%;
+
−
min-height: 100%;
+
−
background-image: url(https://static.igem.org/mediawiki/2017/0/00/T--AQA_Unesp--lactis_background.png);
+
−
background-repeat: no-repeat;
+
−
background-position: center;
+
−
height: 280px;
+
−
display: flex;
+
−
justify-content: center;
+
−
align-items: center;
+
−
}
+
−
+
−
.coming-soon h1 {
+
−
text-align: center;
+
−
font-size: 40pt;
+
−
font-family: 'Quicksand', sans-serif;
+
−
color: white;
+
−
text-shadow: 0px 0px 10px black;
+
−
}
+
−
+
−
.synbio {
+
−
width: 100%;
+
−
position: absolute;
+
−
bottom: 0;
+
−
align-items: center;
+
−
display: flex;
+
−
flex-direction: row;
+
−
flex-wrap: wrap;
+
−
justify-content: center;
+
−
}
+
−
+
−
.igem {
+
−
width: 100%;
+
−
position: absolute;
+
−
top: 0;
+
−
align-items: center;
+
−
display: flex;
+
−
flex-direction: row;
+
−
flex-wrap: wrap;
+
−
justify-content: center;
+
−
}
+
−
+
−
.igem h1 {
+
−
text-align: center;
+
−
font-size: 34pt;
+
−
font-family: 'Quicksand', sans-serif;
+
−
color: white;
+
−
text-shadow: 0px 0px 10px black;
+
−
}
+
  
 +
#gold-award { float:left; }
  
 +
</style>
  
  
−
/***************************************************** RESPONSIVE STYLING ****************************************************/
+
<div class="foto-grande">
  
−
/* IF THE SCREEN IS LESS THAN 1200PX */
+
<div id="titleinsubiota">
−
@media only screen and (max-width: 1200px) {
+
<div style="width:950px; margin: 0 auto">
  
−
#content {width:100%; }
+
<img src="https://static.igem.org/mediawiki/2017/e/ec/Gold-award-aqaunesp.png" width="200px" id="gold-award">
−
.igem_2017_menu_wrapper {width:15%; right:0;}
+
<div class="insubiota-text">INSUBIOTA</div>
−
.highlight {padding:10px 0px;}
+
<div class="insubiota-subtext">treating diabetes with genetically engineered probiotic</div>
−
.igem_2017_menu_wrapper #display_menu_control { display:none; }
+
−
#menu_content { display:block;}
+
−
.menu_button.direct_to_page {padding-left: 17px;}
+
−
+
−
}
+
  
−
/* IF THE SCREEN IS LESS THAN 800PX */
+
</div>
−
@media only screen and (max-width: 800px) {
+
</div>
  
−
.igem_2017_menu_wrapper { width:100%; height: 15%; position:relative; left:0%;}
+
</div>
−
.igem_2017_content_wrapper {width:100%; margin-left:0px;}
+
−
.column.half_size  {width:100%; }
+
−
.column.full_size img, .column.half_size img {  width: 100%; padding: 10px 0px;}
+
−
.highlight {padding:15px 5px;}
+
−
.igem_2017_menu_wrapper #display_menu_control { display:block; }
+
−
#menu_content { display:none;}
+
−
.igem_2017_menu_wrapper .menu_button .expand_collapse_icon { width: 5%; }
+
−
.menu_bottom_padding {display:none;}
+
−
.menu_button.direct_to_page { padding-left: 36px; }
+
−
}
+
  
 +
<div style="width:100%; margin: 0 auto; background-color: #44558f">
 +
 +
<div id="abstract">ABSTRACT</div>
 +
 +
<div style="max-width:1000px; font-size:1.5em; margin: 2% auto; line-height:1.5; text-align:justify; color: white; padding-top:2%; padding-bottom: 2%">
 +
Our project was inspired on the alarming and increasing number of diabetic people, especially diabetes mellitus type 1 patients, who are insulin dependent. The lack of less invasive treatments has motivated us to develop a new treatment based on the probiotic bacteria <i>Lactococcus lactis</i>, that was engineered to produce a single-chain analog insulin in human diabetic’s microbiota. The bacteria will be able to produce the insulin associated with a secretion signal sequence and cell-penetrating peptides, to ensure its uptake. Moreover, the synthesis of the insulin will be controlled by the natural bacteria system of catabolite repression with regulation by a small RNA. At the presence of glucose, the insulin gene expression will be activated, and then, it will be ready to be secreted and absorbed, reaching the blood and performing its biological function. Also, in order to contain the release of our engineered probiotic to the environment, we built a kill switch based on light exposure that uses the CRISPR/Cas9 system to destroy essential genes for the bacterial survival. The final product could be a fermented milk or a lyophilized that could be easily ingested by patients.
 +
 +
</div>
 +
</div>
 +
 +
<div style="text-align:center">
 +
<video width="1000" controls>
 +
<source src="https://static.igem.org/mediawiki/2017/a/a7/Aqaunesp-video-insubiota.mp4" type="video/mp4">
 +
</video>
 +
</div>
 +
 +
<style>
 +
#buttons { max-width:1100px; margin:3% auto; display:table}
 +
 +
.botao-link {
 +
position: relative;
 +
width: 150px;
 +
float:left;
 +
margin:5px;
 +
}
 +
 +
 +
.image {
 +
  display: block;
 +
  width: 150px;
 +
  height: 150px;
 +
}
 +
 +
.overlay {
 +
  position: absolute;
 +
  top: 0;
 +
  bottom: 0;
 +
  left: 0;
 +
  right: 0;
 +
  height: 100%;
 +
  width: 100%;
 +
  opacity: 0;
 +
  transition: .5s ease;
 +
  background-color: #008CBA;
 +
border-radius:50%;
 +
}
 +
 +
#projectdesc {background-color: RGB(255,208,91)}
 +
#design {background-color: RGB(159,159,226)}
 +
#hpp {background-color: RGB(50,74,94)}
 +
#team {background-color: RGB(255,76,58)}
 +
 +
.botao-link:hover .overlay {
 +
  opacity: 1;
 +
}
 +
 +
.text {
 +
  color: white;
 +
  font-size: 20px;
 +
  position: absolute;
 +
  top: 50%;
 +
  left: 50%;
 +
  transform: translate(-50%, -50%);
 +
  -ms-transform: translate(-50%, -50%);
 +
}
  
−
 
−
 
−
/* special class that the system uses to make sure the team wants a page to be evaluated */
 
−
.judges-will-not-evaluate {
 
−
    width: 96.6%;
 
−
  margin: 5px 15px;
 
−
  display: block;
 
−
border: 4px solid #3399ff;
 
−
    font-weight: bold;
 
−
}
 
−
 
 
</style>
 
</style>
  
 +
<div id="buttons">
  
−
<!--- THIS IS WHERE THE HTML BEGINS --->
+
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/Description">
 +
<img src="https://static.igem.org/mediawiki/2017/f/f5/Aqaunesp-projectdescription-icon.png" class="image">
 +
<div class="overlay" id="projectdesc">
 +
<div class="text">project description</div>
 +
</div>
 +
</a>
 +
</div>
  
 +
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/Applied_Design">
 +
<img src="https://static.igem.org/mediawiki/2017/c/cd/AQAUnesp-design-icon.png" class="image">
 +
<div class="overlay" id="design">
 +
<div class="text">design</div>
 +
</div>
 +
</a>
 +
</div>
  
 +
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/Results">
 +
<img src="https://static.igem.org/mediawiki/2017/7/7c/Aqaunesp-results-icon.png" class="image">
 +
<div class="overlay" id="projectdesc">
 +
<div class="text">results</div>
 +
</div>
 +
</a>
 +
</div>
  
−
</head>  
+
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/HP/Silver">
 +
<img src="https://static.igem.org/mediawiki/2017/0/0a/AQAUnesp-hp-icon.png" class="image">
 +
<div class="overlay" id="hpp">
 +
<div class="text">human practices</div>
 +
</div>
 +
</a>
 +
</div>
 +
 
 +
<div class="botao-link">
 +
<a href="https://2017.igem.org/Team:AQA_Unesp/Team">
 +
<img src="https://static.igem.org/mediawiki/2017/b/bd/AQAUnesp-team-icon.png" class="image">
 +
<div class="overlay" id="team">
 +
<div class="text">team</div>
 +
</div>
 +
</a>
 +
</div>
 +
 
 +
</div>
  
−
<body>
 
−
<div class="igem"><h1>iGEM 2017</h1></div>
 
−
<div class="coming-soon"><h1>coming soon...</h1></div>
 
−
<div class="synbio"><img src="https://static.igem.org/mediawiki/2017/thumb/e/e2/T--AQA_Unesp--logoTime.png/800px-T--AQA_Unesp--logoTime.png" width="250px"></div>
 
 
</body>
 
</body>
 
</html>
 
</html>
 +
{{AQA_Unesp_btm}}

Latest revision as of 18:13, 15 December 2017



iGEM AQA_Unesp

INSUBIOTA
treating diabetes with genetically engineered probiotic
ABSTRACT
Our project was inspired on the alarming and increasing number of diabetic people, especially diabetes mellitus type 1 patients, who are insulin dependent. The lack of less invasive treatments has motivated us to develop a new treatment based on the probiotic bacteria Lactococcus lactis, that was engineered to produce a single-chain analog insulin in human diabetic’s microbiota. The bacteria will be able to produce the insulin associated with a secretion signal sequence and cell-penetrating peptides, to ensure its uptake. Moreover, the synthesis of the insulin will be controlled by the natural bacteria system of catabolite repression with regulation by a small RNA. At the presence of glucose, the insulin gene expression will be activated, and then, it will be ready to be secreted and absorbed, reaching the blood and performing its biological function. Also, in order to contain the release of our engineered probiotic to the environment, we built a kill switch based on light exposure that uses the CRISPR/Cas9 system to destroy essential genes for the bacterial survival. The final product could be a fermented milk or a lyophilized that could be easily ingested by patients.
Team: AQA_Unesp